Lantheus (LNTH) Downgraded to “Hold” at Zacks Investment Research
Zacks Investment Research cut shares of Lantheus (NASDAQ:LNTH) from a buy rating to a hold rating in a report published on Tuesday.
According to Zacks, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States. “
LNTH has been the subject of a number of other reports. BidaskClub upgraded Lantheus from a hold rating to a buy rating in a research report on Wednesday, December 27th. Jefferies Group restated a buy rating and issued a $22.00 price objective on shares of Lantheus in a research report on Thursday, October 12th. Credit Suisse Group boosted their price objective on Lantheus from $19.00 to $23.00 and gave the company a neutral rating in a research report on Friday, November 3rd. Wells Fargo & Co upgraded Lantheus from a market perform rating to an outperform rating in a research report on Thursday, November 2nd. Finally, ValuEngine cut Lantheus from a buy rating to a hold rating in a research report on Friday, December 1st. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus price target of $24.75.
Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.04. The business had revenue of $79.94 million during the quarter, compared to analysts’ expectations of $77.18 million. Lantheus had a negative return on equity of 46.45% and a net margin of 9.59%. The business’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the business earned $0.15 earnings per share. sell-side analysts anticipate that Lantheus will post 1.05 EPS for the current fiscal year.
In other news, SVP Timothy G. Healey sold 11,314 shares of Lantheus stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $21.51, for a total value of $243,364.14. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO John W. Crowley sold 3,866 shares of Lantheus stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $23.52, for a total value of $90,928.32. The disclosure for this sale can be found here. Insiders sold 48,752 shares of company stock worth $1,077,129 over the last ninety days. Corporate insiders own 2.30% of the company’s stock.
Several large investors have recently modified their holdings of LNTH. Vanguard Group Inc. boosted its stake in shares of Lantheus by 87.5% in the second quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after acquiring an additional 689,954 shares during the last quarter. State Street Corp boosted its stake in Lantheus by 3,932.8% during the second quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock worth $10,891,000 after buying an additional 601,714 shares during the last quarter. Peregrine Capital Management LLC acquired a new position in Lantheus during the third quarter worth $8,062,000. Ameriprise Financial Inc. acquired a new position in Lantheus during the second quarter worth $7,396,000. Finally, Dimensional Fund Advisors LP boosted its stake in Lantheus by 73.7% during the third quarter. Dimensional Fund Advisors LP now owns 911,311 shares of the medical equipment provider’s stock worth $16,221,000 after buying an additional 386,771 shares during the last quarter. 91.22% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/lantheus-lnth-downgraded-to-hold-at-zacks-investment-research/1839500.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.